Paradoxical effects of anti-TNF-α agents in inflammatory diseases
- 10 December 2013
- journal article
- review article
- Published by Informa UK Limited in Expert Review of Clinical Immunology
- Vol. 10 (1), 159-169
- https://doi.org/10.1586/1744666x.2014.866038
Abstract
Anti-TNF agents represent a major breakthrough in the management of inflammatory diseases. Among the side effects of these agents are the so-called paradoxical effects described in this review. They represent new onset or exacerbation of a condition (symptom/disease), usually improved with TNF blockers. These paradoxical effects are mainly psoriasiform skin reactions, uveitis and granulomatous diseases (such as sarcoidosis and Crohn's disease). Infrequent and probably underreported, they should be discussed from the viewpoint of spontaneous features of the underlying disease (e.g., uveitis or psoriasis in a case of spondyloarthritis). The causal mechanism of occurrence is still a matter of debate, but may implicate an imbalance of cytokines toward interferons, chemokines and probably IL-17. These reactions may raise differential diagnosis problems. Symptoms resolve, most of the time, due to the discontinuation of the anti-TNF agent or sometimes a switch to another TNF blocker; but in some cases, it is a class effect that could lead to the withdrawal of all anti-TNF agents.Keywords
This publication has 55 references indexed in Scilit:
- A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS studyAnnals Of The Rheumatic Diseases, 2013
- TNFα: Activator or inhibitor of regulatory T cells?Joint Bone Spine, 2012
- Anti-TNF therapyBest Practice & Research Clinical Rheumatology, 2011
- TNF alpha antagonist therapy and safety monitoringJoint Bone Spine, 2011
- Induction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 casesJournal of Dermatological Treatment, 2009
- Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: A literature review and potential mechanisms of actionArthritis Care & Research, 2008
- Onset or exacerbation of cutaneous psoriasis during TNFα antagonist therapyJoint Bone Spine, 2008
- Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor α therapy: results from the British Society for Rheumatology Biologics RegisterAnnals Of The Rheumatic Diseases, 2008
- Tumor necrosis factor antagonist mechanisms of action: A comprehensive reviewPharmacology & Therapeutics, 2008
- TNF‐mediated inflammatory diseaseThe Journal of Pathology, 2007